ROKIT America, Inc.
Direct-to-consumer NMN and longevity supplement brand under Korean parent ROKIT Healthcare.
On the record
Checkpoint: 20/20 BioLabs AI multi-cancer prediction platform US launch, tied to ROKIT's disputed AI partner
The call
A single-SKU-heavy supplement brand riding a Korean parent's unproven regeneration story, now facing an illiquid listing and open questions about its AI partner.
ROKIT America makes and sells NMN, a supplement claimed to support aging and energy, directly to consumers online. The company faces fierce competition from ProHealth Longevity, Double Wood, Elysium Health, and many others selling nearly identical products, and there is nothing unique about ROKIT America's business that a competitor cannot quickly copy or that AI-powered marketing tools cannot replicate. The company's planned stock listing fell apart in July 2026 because of concerns about its parent company's AI partner's credibility and because too few shares were available to trade. The one thing that could change the picture is if the parent company's kidney regeneration trial shows real results, which could rebuild trust in the entire brand and give ROKIT America a reason to exist beyond being another NMN seller.
Why
01
AI pressure: Generative AI ad and personalization tools (e.g. Meta Advantage+, TikTok Smart Performance). AI ad tools let any rival copy ROKIT's marketing and targeting cheaply, eroding the one edge a small DTC brand could have. Could AI do the core job? Yes, likely.
02
Bigger players: Established NMN and longevity brands: ProHealth Longevity, Double Wood, Elysium Health. Dozens of near-identical NMN and spermidine products already sell online at similar prices with no switching cost for buyers. Could a giant copy it? Yes, easily.
03
What protects it. Its Korean parent's regeneration research story and Coupang distribution give it reach and a narrative small rivals lack, though unproven.
What would change this call
ROKIT America refiles for Nasdaq listing with disclosed free-float ratio. Shows whether the ~10% float and liquidity problem that forced withdrawal has been fixed.
Public resolution or further fallout on the U.S. AI-partner (20/20 BioLabs) legitimacy questions. Shows whether the credibility issue that contributed to the listing pull is resolved or worsening.
Reported customer acquisition cost trend in ROKIT America's core supplement business over the next two quarters. Shows whether the single-SKU NMN business can sustain growth or is being squeezed by rising marketing costs.
Public resolution or further fallout on the U.S. AI-partner (20/20 BioLabs) legitimacy questions. Shows whether the credibility issue that contributed to the listing pull is resolved or worsening.
Reported customer acquisition cost trend in ROKIT America's core supplement business over the next two quarters. Shows whether the single-SKU NMN business can sustain growth or is being squeezed by rising marketing costs.
Key numbers
- TTM revenue $7.43M, up 139.9% year over year
- Nasdaq listing withdrawn over ~10% free float
- Parent ROKIT Healthcare stock fell ~20% on news
Named risks
- Nasdaq listing withdrawn July 27-28, 2026 due to ~10% free float, no confirmed relisting date.
- Unresolved public controversy over U.S. AI partner 20/20 BioLabs legitimacy tied to parent announcements.
- Heavy dependence on a single NMN product line with rising customer acquisition costs per third-party analysis, 2026-05-12.
- Core equity narrative rests on parent's unproven organ-regeneration platform, not IP held by ROKIT America itself.
- Direct-to-consumer supplement marketing is easily replicated and increasingly commoditized by generative AI tools.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Elysium Health | contesting | Named as direct NMN/longevity supplement peer in industry comparison, 2026-05-18 |
| ProHealth Longevity | contesting | Cited as near-identical DTC NMN competitor with no structural barrier to entry, 2026-05-18 |
| Double Wood Supplements | contesting | Listed among commodity NMN peers competing on same SKUs and pricing, 2026-05-18 |
| Doximity | losing to | Established AI healthcare platform posted $145.4M quarterly revenue vs ROKIT's unproven AI diagnostic ambitions, 2026 spring |
Questions people ask
- Did ROKIT America complete its Nasdaq IPO in 2026?
- No. ROKIT America voluntarily withdrew its Nasdaq Global Market listing application on July 27-28, 2026, after Nasdaq flagged a post-listing free float of only about 10 percent, and amid scrutiny of a U.S. AI partner's legitimacy. The company says it intends to refile once free float is increased, but no new date has been set.
- Is ROKIT America profitable?
- Third-party data from stockanalysis.com shows trailing-twelve-month revenue of $7.43 million as of July 21, 2026, up 139.9 percent year over year, with gross profit of $5.08 million versus $2.02 million prior period, but no confirmed net income figure or audited profitability has been disclosed.
- Who owns ROKIT America?
- ROKIT America is majority owned by its Korean parent, ROKIT Healthcare, Inc. (KOSDAQ: 376900), which was expected to retain roughly 90 percent of shares after the IPO, per reporting dated May 11, 2026. Funding to date has come through intercompany agreements with the parent, not outside investors.
- Who are ROKIT America's biggest competitors?
- ROKIT America competes in the crowded NMN and longevity-supplement market against near-identical direct-to-consumer brands including ProHealth Longevity, Double Wood Supplements, Renue By Science, Nutricost, and Elysium Health, as identified in industry comparisons published May 18, 2026.
- Could AI replace ROKIT America's business?
- ROKIT America's core direct-to-consumer supplement marketing, copywriting, and customer acquisition workflows are highly exposed to generative AI commoditization, since dozens of near-identical NMN brands already use similar tactics, and the company has no proprietary tech moat of its own as of 2026.
- Is it safe to invest in or join ROKIT America right now?
- As of July 28, 2026, ROKIT America pulled its Nasdaq listing over free-float concerns and an unresolved controversy about a U.S. AI partner's identity, and parent ROKIT Healthcare's stock fell about 19.7 percent to 31,450 won on July 29, 2026, signaling active investor uncertainty.
Timeline
- 2026-07-29Parent ROKIT Healthcare stock falls about 19.7 percent to 31,450 won after withdrawal news
- 2026-07-28ROKIT America voluntarily withdraws Nasdaq Global Market listing application
- 2026-07-24Parent signs MOU with U.S. firm 20/20 BioLabs for AI cancer-prediction platform
- 2026-07-12Parent ROKIT Healthcare launches world-first AI kidney-regeneration clinical trial
- 2026-06-23SEC completes review of ROKIT America's S-1 registration statement
- 2026-05-08ROKIT America sets IPO terms: $25 million at $8.50 to $10.50 per share
- 2026-05-03Parent expands AI cartilage-regeneration trial to 13 institutions, 100-plus patients
- 2026-04-15ROKIT America files Form S-1 with SEC, initially seeking up to $35 million
- 2026-03-12ROKIT America launches distribution in South Korea via Coupang
Revision history
29 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- ROKIT HEALTHCARE Inc. Voluntarily Withdraws Nasdaq Listing Application (2026-07-28)
- Rokit Healthcare Shares Plunge Nearly 20% After Nasdaq Listing Withdrawal (2026-07-28)
- Anti-aging supplement maker ROKIT America sets terms for $25 million IPO (2026-05-07)
- ROKIT America (RKAM) Income Statement
- ROKIT America Accelerates Expansion in the Americas (2025-09-30)
- ROKIT America Targets $25 Million U.S. IPO At High Valuation (2026-05-12)
- rokit_s1.htm (2026-04-15)
- Rokit America files Nasdaq Global listing as Korea parent plans 90% stake (2026-05-11)
- Rokit America Inc. Financial Statements, NASDAQ
- NMN, ROKIT AMERICA
- ROKIT America brings the future of longevity to Korea through Coupang (2026-03-12)
- Rokit Healthcare Launches World's First Kidney Regeneration Clinical Trial (2026-07-12)